close
MENU
How to guide
How to guide
Home
NBR Marketplace
The NBR List
NBR Video

Categories

General Business Investment Economics Te Ao Māori Politics Infrastructure Australia Tech & Innovation Finance Law Professional Services Primary Industries Retail Property Deals Marketing & Media Tourism Energy Luxury Property Aviation News Comings & Goings

Analysis

All Economy Matters Edwards on Politics Hunter’s Corner Last Word Margin Call On the Money Shoeshine Underarm NBR Focus

Featured

The NBR Podcast Morning Brew The Grind Entrepreneurs Your Business Beehive Banter Toil & Trouble Market Outlook Dollars & Sense Local Edge Private Bin Audio Articles Podcasts NZ Aviation News Back Issues NBR Radar (Archive) Opinion (Archive) NBR Rich List (Archive)
General Business
11 mins to read

Pictor’s long, slow road to commercialisation speeds up

Animal health could be a bigger money-spinner than human.

Pictor developed patented immune-diagnostic technology platform that allowed simple and reliable blood testing.

Fiona Rotherham Wed, 13 Jul 2022

Sixteen years ago husband and wife team Anand and Sarita Kumble set up Auckland-based biotech company Pictor to make diagnostic testing for infectious diseases affordable for emerging countries.

The biochemists developed a patented immune-diagnostic technology platform that allowed simple and

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
View terms and conditions.
Individual
Group membership
NBR Marketplace

Smartphone Only Subscription

NZ$29.95 / monthly

Monthly Premium Online Subscription

NZ$49.95 / monthly

Smartphone Only Annual Subscription

NZ$299.00 / yearly

Yearly Premium Online Subscription

NZ$499.00 / yearly

Premium Group Membership 10 Users

NZ$385+GST / monthly

$38.5 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$660+GST / monthly

$33 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1375+GST / monthly

$27.5 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$2100+GST / monthly

$21 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$999.00 / yearly

Already have an account? Login
Fiona Rotherham Wed, 13 Jul 2022
Contact the Writer: fiona@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Tags
Pictor Howard Moore Covid-19 Natasha Gordon Matt Redstone M.bovis Johne's disease Anand and Sarita Kumble

Free News Alerts

Sign up to get the latest stories and insights delivered to your inbox – free, every day.

I’m already subscribed/joined
Related News
Politics

Biosecurity receives $111m in budget 2022
General Business

Govt/industry joint programme sees M. bovis almost eradicated

Investment
1

Bogoievski and K1W1 help local biotech firm address US Covid surveillance market
General Business
1

Pictor to launch new Covid antibody test next month
General Business

Diagnostics firm Pictor expects revenue boom from Covid partnership

Free News Alerts

Sign up to get the latest stories and insights delivered to your inbox – free, every day.

I’m already subscribed/joined
Related News
Politics

Biosecurity receives $111m in budget 2022
General Business

Govt/industry joint programme sees M. bovis almost eradicated

Investment
1

Bogoievski and K1W1 help local biotech firm address US Covid surveillance market
General Business
1

Pictor to launch new Covid antibody test next month
General Business

Diagnostics firm Pictor expects revenue boom from Covid partnership
Pictor’s long, slow road to commercialisation speeds up
General Business,
94793
true
Subscribe Login